Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Novel Therapy to Preserve Beta Cell Function in New Onset Type 1 Diabetes

This study has been terminated.
(Changes to study personnel.)
Sponsor:
Information provided by (Responsible Party):
James Balow, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
ClinicalTrials.gov Identifier:
NCT00837759
First received: February 4, 2009
Last updated: December 31, 2012
Last verified: December 2012

February 4, 2009
December 31, 2012
February 2009
March 2011   (final data collection date for primary outcome measure)
Change in C-peptide [ Time Frame: 6 months following the protocol subject's randomization/treatment initiation ] [ Designated as safety issue: No ]
Changes in beta cell function (MMTT C-peptide AUC_mean
Complete list of historical versions of study NCT00837759 on ClinicalTrials.gov Archive Site
  • Glycemia Control (Change in HbA1c Level) [ Time Frame: 6 months following the protocol subject's randomization/treatment initiation ] [ Designated as safety issue: No ]
  • Change in Insulin Dose [ Time Frame: 6 months following the protocol subject's randomization/treatment initiation ] [ Designated as safety issue: No ]
  • Change in Anti-GAD Autoantibody Titers [ Time Frame: 6 months following the protocol subject's randomization/treatment initiation ] [ Designated as safety issue: No ]
  • Change in Anti-IA2 Titer [ Time Frame: 6 months following the protocol subject's randomization/treatment initiation ] [ Designated as safety issue: No ]
  • Change in ZnT8 Autoantibody Titer [ Time Frame: 6 months following the protocol subject's randomization/treatment initiation ] [ Designated as safety issue: No ]
Glycemia control, insulin requirements, changes in immune function
Not Provided
Not Provided
 
Novel Therapy to Preserve Beta Cell Function in New Onset Type 1 Diabetes
Novel Therapy Combining Regenerative Stimuli Immunomodulation to Preserve Beta Cell Function in New Onset Type 1 Diabetes

Background:

  • Type 1 diabetes (T1D) occurs when the immune system attacks insulin-producing cells (beta cells) in the pancreas, resulting in their death.
  • Insulin injections currently are the best method for controlling blood sugar in individuals with T1D. However, animal studies have shown that the drugs sitagliptin and lansoprazole can help reverse beta cell damage or develop new beta cells. In addition, Diamyd has been shown to weaken the immune process that attacks pancreatic beta cells.

Objectives:

  • To find out whether a combination treatment of sitagliptin, lansoprazole, and Diamyd will help maintain functioning beta cells and/or cause new beta cells to form.
  • To determine how the drug combination affects insulin doses and blood sugar control.
  • To determine whether the drug combination affects the immune response involved in T1D.

Type 1 diabetes (T1D) is the end result of immune mediated beta-cell destruction. It is generally accepted that at the time of T1D is diagnosed, an individual has lost most (60-80%) of his/her beta cell function. The loss of insulin-producing beta cells is believed to occur over a period of months to years and individuals can retain some endogenous insulin production even years after clinical diagnosis of diabetes. The presence of residual beta cell mass may signify a complex interplay between the auto-destructive immune response and the capacity for limited beta cell regeneration. When initiated at T1D onset, immunosuppression has been shown to preserve beta cell function, but with significant and limiting toxicities. Selectively targeting the pathogenic T-cells involved in T1D development and progression could achieve the same objective with less toxicity. Various studies of the non-obese diabetic (NOD) mouse model of spontaneous autoimmune diabetes have demonstrated that administering glutamic acid decarboxylase (GAD65), a beta cell autoantigen, can prevent the immune destruction and delay or prevent diabetes onset. Preclinical studies have also identified several growth factors, including epidermal growth factor (EGF), glucagon-like peptide 1 (GLP-1), and gastrin, that appear to promote beta cell proliferation. We seek to test the potential for preserving beta cell function early in the disease course of T1D by combining antigen-specific immunomodulation with regenerative stimuli.

Interventional
Phase 2
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Diabetes Mellitus Type 1
  • Autoimmune Diabetes
  • Drug: Insulin
    N/A
  • Drug: Lansoprazole
    N/A
  • Drug: Sitagliptin
    N/A
  • Biological: Diamyd
    N/A
  • Drug: GAD65 (Diamyd)
    N/A
T1D group
This study was terminated prior to full subject accrual because of changes to study personnel. The original study design was changed from a double-blind, placebo-controlled study to an open-label pilot study in order to collect safety data on enrolled subjects prior to study termination.
Interventions:
  • Drug: Insulin
  • Drug: Lansoprazole
  • Drug: Sitagliptin
  • Biological: Diamyd
  • Drug: GAD65 (Diamyd)

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
7
March 2011
March 2011   (final data collection date for primary outcome measure)
  • INCLUSION CRITERIA:

    1. Recently diagnosed (within the preceding 4 months of screening) diabetes clinically consistent with T1D:

      A. Positive for anti-GAD antibody.

      B. BMI between 19 and 28 kg/m2; for those between the ages of 16 to 18, the BMI must be within 10th to 90th percentile for the age.

    2. Ages between 16 and 30 years, inclusive
    3. Random plasma C-peptide level of equal to or greater than 0.20 nmol/L
    4. Willingness and ability to institute intensive insulin-based glucose management.

EXCLUSION CRITERIA:

  1. Diabetic nephropathy with a creatinine clearance less than 60 cc/min or 24 hour urine albumin greater than 300 mg
  2. Insulin requirements greater than 0.8 units/kg/day at the end of the run-in period
  3. Regular use of a proton pump inhibitor within 3 months of enrollment
  4. Use of GLP-1R agonist or DPP-4 inhibitor within 6 months prior to enrollment
  5. Use of immunosuppressive therapy in the preceding 12 months
  6. Evidence of chronic infection, for example, known human immunodeficiency virus (HIV) or hepatitis
  7. History of any malignancy other than a treated basal or squamous skin cancer
  8. Any chronic medical condition to unduly increase risk for the potential enrollee as judged by study investigators
  9. Pregnancy, breastfeeding or planned pregnancy within two years, women of reproductive age not using an effective mode of contraception and unwilling to continue adequate contraception until 1 year after the last study drug administration
  10. Any other co-existing condition/circumstances that would make patient unsuitable to participate in the study, as deemed by the investigators. For example, study investigators would exclude any potential candidate with any of the following (but the list is not inclusive):

A. Clinically significant past history of an acute reaction to vaccines or other drugs

B. Recent participation in other clinical trials with a new chemical entity

C. A history of alcohol or drug abuse

D. Significant neurological conditions like epilepsy, head trauma, or cerebrovascular accidents

E. Individuals with significant gastrointestinal disorders determined by the study investigators to influence either study safety or data interpretation. Such conditions include but are not limited to gastroparesis and gastric bypass surgery

F. Individuals with conditions prone to hypergastrinemia (Zollinger-Ellison syndrome, use of histamine-2 receptor blockers) or hypogastrinemia (gastric surgery).

Both
16 Years to 30 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00837759
090056, 09-DK-0056, 09-DK-0056
No
James Balow, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Not Provided
Study Director: Balow James, MD National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
National Institutes of Health Clinical Center (CC)
December 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP